$0.351
-0.018 (-5.11%)收盤時
SLXN 資訊
SLXN 事件
Silexion Therapeutics Prices Public Offering at $0.65 per Share
Silexion Therapeutics announced the pricing of a public offering of an aggregate of 3,846,161 of the Company's ordinary shares and series E warrants to purchase up to 3,846,161 ordinary at a combined public offering price of $0.65 per share (or per ordinary share equivalent) and accompanying warrants. The series E warrants will have an exercise price of $0.65 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about August 13, 2026, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Silexion Therapeutics Files to Sell Ordinary Shares and Warrants
Silexion Therapeutics files to sell ordinary shares, warrants, no amount given
Silexion Therapeutics Files to Sell 859,609 Ordinary Shares
Silexion Therapeutics files to sell 859,609 ordinary shares for holders
Silexion Therapeutics Initiates GMP Clinical Batch Manufacturing of SIL204
Silexion Therapeutics announced the initiation of good manufacturing practice, or GMP, clinical batch manufacturing of SIL204, the company's siRNA therapy targeting mutated KRAS, in support of the planned upcoming Phase 2/3 clinical trial in locally advanced pancreatic cancer. Additionally, the company announced that it has received approval from the Helsinki Ethics Committee of Tel Aviv Sourasky Medical Center for the planned Phase 2/3 trial of SIL204 at its site, a leading Israeli oncology center. The clinical batches currently in production will serve as the investigational medicinal product supply used to treat the first patients to be enrolled in the safety run-in segment of the Phase 2/3 trial. The drug substance for SIL204 was successfully manufactured in 2025 by a specialist global oligonucleotide contract development and manufacturing organization. The drug product, the finished clinical formulation administered to patients, is now being manufactured by Catalent at its facility in Limoges, France.
Silexion Therapeutics Submits CTA for SIL204 Clinical Trial
Silexion Therapeutics announced the recent successful submission of a clinical trial application, or CTA, to Germany for its planned Phase 2/3 clinical trial of its lead, small interfering RNA product candidate, SIL204, in patients with locally advanced pancreatic cancer. The CTA was submitted through the EU Clinical Trials Information System, with Germany serving as the Reporting Member State - the country that will lead the scientific assessment of the trial across the European Union.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。